{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Iovance Biotherapeutics, Inc. (\"Iovance\"), headquartered in San Carlos, CA.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2024/12/02/2024-28081.html","cfr_references":[],"citation":"89 FR 95224","comment_url":null,"comments_close_on":"2024-12-17","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before December 17, 2024 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2024-28081","effective_on":null,"end_page":95225,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2024/12/02/2024-28081.xml","html_url":"https://www.federalregister.gov/documents/2024/12/02/2024-28081/prospective-grant-of-an-exclusive-patent-license-vaccine-augmented-tumor-infiltrating-lymphocytes","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2024-28081?publication_date=2024-12-02","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2024-12-02/2024-28081/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":602,"last_updated":"2026-10-24 06:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-12-02/pdf/2024-28081.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-28081.pdf?1732887927","publication_date":"2024-12-02","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2024/12/02/2024-28081.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2024-11-30T09:10:04Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":95224,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Vaccine Augmented Tumor Infiltrating Lymphocytes for the Treatment of Cancer","toc_doc":"Vaccine Augmented Tumor Infiltrating Lymphocytes for the Treatment of Cancer","toc_subject":"Licenses; Exemptions, Applications, Amendments, etc.","topics":[],"type":"Notice","volume":89}